Latest Revenue Guidance News

Bubs Australia has delivered a robust first half for FY26, powered by a 48% revenue surge in the US, prompting an upgrade to its full-year earnings guidance.

TZ Limited reported a $1.92 million loss for the half-year ending December 2025, with revenues of $5.4 million impacted by delayed US projects and integration challenges from its Keyvision acquisition. The company is banking on large tenders and expanding Microsoft data centre sales to drive recovery.

Change Financial has reported a strong first half for FY26 with record revenue growth and its first-ever half-year profit, underpinned by expanding recurring revenues and operational efficiencies.

Acrow Ltd reported a robust 23% revenue increase in 1H FY26, driven by its expanding Industrial Access division, even as net profit fell 22% amid Queensland market softness. The company’s strategic investments and acquisitions position it well for future growth.

SKS Technologies Group has reported a robust half-year performance, driven by a landmark $130 million data centre contract and a strategic acquisition, positioning it strongly for FY26 growth.

Fisher & Paykel Healthcare has raised its full-year revenue and profit forecasts for FY26, buoyed by strong hospital product growth and favourable exchange rates, while navigating the complexities of a recent US Supreme Court tariff ruling.

Megaport Limited reported a robust 49% increase in Annual Recurring Revenue to A$338 million for H1 FY26, driven by organic growth and key acquisitions. The company raised its FY26 revenue guidance and delivered strong EBITDA growth while expanding its global footprint.

Atturra Limited confirms its FY26 revenue and EBITDA guidance, acknowledging a contract termination impact in H1 but optimistic about a stronger second half.

Acrow Limited reaffirms its first half FY26 revenue guidance with a 22% increase year-on-year, driven by robust demand in key Australian regions and strategic capital investments.

PEXA Group has announced its strategic exit from majority-owned Digital Solutions businesses, triggering a $26 million impairment and a restatement of its FY26 financial guidance. The move signals a sharper focus on core operations amid restructuring costs.

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.